Is the ChondroFiller injection really non-surgical?
For patients weighing up joint-preservation options, the practical question is usually straightforward: does this mean theatre, an incision, or a general anaesthetic? For the ChondroFiller injection, the answer to all three is no. It is performed as an outpatient procedure, guided by ultrasound, through a fine needle — with no cut, no stitches, and no surgical recovery. That is what makes it genuinely non-surgical, not just marketed as such.
ChondroFiller itself is a Class III CE-marked medical device: a type I collagen hydrogel scaffold made by Meidrix Biomedicals in Germany and imported into the UK under prescription. It is acellular — meaning it contains no cells — and self-gels in approximately three to five minutes once placed in the joint, forming a porous three-dimensional matrix that may recruit the patient's own progenitor cells to support cartilage regeneration. The injection is the non-surgical delivery pathway for this scaffold, suited to accessible lesions and appropriately selected joints.
Why avoiding surgery matters for joint care
Non-surgical treatment avoids the disruption that even minimally invasive surgery entails. There is no incision to heal, no surgical scar, no general anaesthetic risk, and no extended period of restricted weight-bearing. For many patients with focal joint wear, early osteoarthritis, or accessible cartilage lesions, this difference is clinically meaningful as well as practically convenient.
The benefits of avoiding surgery extend to recovery. Patients who receive the ChondroFiller injection as an outpatient typically experience little post-procedural discomfort and return to normal daily activities promptly, though individual responses vary. It is important to hold expectations at an appropriate level: the ChondroFiller injection is best understood as a supportive, joint-preserving intervention — evidence suggests it may add a protective, cushioning layer over worn surfaces and provide a scaffold for biological repair, but it is not a cure and cannot reverse established arthritis.
How the ChondroFiller injection works
Under real-time ultrasound guidance, a clinician passes a fine needle through the skin into the joint space and deposits the collagen gel at the target site. Ultrasound allows precise, targeted placement without the need for an operating theatre. Once in place, the gel self-sets, filling the defect and creating a matrix that is physically supportive and biologically permissive — it gains anchorage via fibrin infiltration and allows host cells to migrate in and begin remodelling the collagen scaffold towards cartilage tissue over subsequent months.
Because ChondroFiller is a collagen-based scaffold rather than a simple lubricant or anti-inflammatory, it is biologically distinct from hyaluronic acid or corticosteroid injections. It is intended to support cartilage regeneration at the defect site, not simply to reduce symptoms temporarily. Clinical experience and published case series indicate benefit in appropriate patients, though individual responses vary and the degree of regeneration cannot be guaranteed.
Who the ChondroFiller injection may suit
The injection pathway is generally considered for patients with focal cartilage lesions or early-to-moderate joint wear where the defect is accessible by injection and the overall joint environment is reasonable. It may be relevant across multiple joints — including the knee, hip (where anatomy permits), ankle, shoulder, and smaller joints such as the thumb base — though suitability depends on individual assessment including imaging review and clinical examination.
The injection is less suited to larger or more complex defects, joints with significant malalignment, or cases where the cartilage loss is advanced. In those situations, a surgical approach may be more appropriate. At London Cartilage Clinic, the surgical option for cartilage repair is the Liquid Cartilage procedure — Professor Paul Y. F. Lee's keyhole (arthroscopic) protocol, which delivers the ChondroFiller scaffold together with biological adjuncts and, where indicated, the patient's own mesenchymal stem cells. Liquid Cartilage is a distinct, operative pathway; it is not the same as the non-surgical ChondroFiller injection. An individual consultation determines which pathway, if either, is appropriate.
What patients typically experience
As a non-surgical outpatient procedure, the ChondroFiller injection usually involves a brief period of rest and protection immediately afterwards, with most patients able to return to normal activities within a short time. Individual experiences vary. There is no surgical recovery in the conventional sense — no wound care, no period of theatre-related rehabilitation — though clinicians may advise on activity modification in the early weeks to allow the scaffold to settle and integrate.
Longer-term outcomes depend on the extent of the defect, joint condition, patient factors, and adherence to any post-procedure guidance. Published case series report improvements in joint comfort and function in appropriately selected patients, but results are not uniform and the procedure should not be presented as reliably curative.
A note on what ChondroFiller is and is not
ChondroFiller is a medical device — a CE-marked collagen scaffold — that can be delivered either by injection (non-surgical, outpatient) or, within the Liquid Cartilage surgical protocol, by arthroscopic placement. The device itself, its CE Class III status, and its published biomechanical and clinical data all belong to ChondroFiller as a product. Liquid Cartilage is not a brand name for ChondroFiller, nor is it simply an injection — it is Professor Lee's surgical technique that uses the scaffold as a component within a broader operative and biologic strategy.
Patients considering any form of cartilage treatment should be clear about whether they are being assessed for a non-surgical injection or a surgical procedure. These are meaningfully different in terms of preparation, recovery, risk profile, and indication.
References
Corain M, Zanotti F, Giardini M, Gasperotti L, Invernizzi E, Biasi V, Lavagnolo U. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage. 2023.
Frequently Asked Questions
- It is delivered by an ultrasound-guided needle as an outpatient procedure — no theatre, no incision, no general anaesthetic. The collagen gel is placed directly into the joint through a fine needle, and patients typically return to normal activities with minimal disruption. It is this delivery pathway that makes it non-surgical, distinct from any operative procedure.
- ChondroFiller is a CE-marked Class III medical device: a type I collagen hydrogel scaffold made by Meidrix Biomedicals in Germany. It is acellular (contains no cells), self-gels in approximately three to five minutes once placed in the joint, and is designed to provide a three-dimensional matrix that supports the migration and activity of the patient's own repair cells. It is a scaffold, not a lubricant or anti-inflammatory.
- These are distinct pathways. The ChondroFiller injection is a non-surgical outpatient procedure — no theatre or anaesthetic. Liquid Cartilage is a keyhole surgical protocol developed by Professor Paul Lee, which delivers the ChondroFiller scaffold arthroscopically alongside biological adjuncts and, where appropriate, the patient's own stem cells. Liquid Cartilage is surgery; the ChondroFiller injection is not. The right pathway depends on individual clinical assessment.
- Recovery is generally straightforward compared with surgery. Most patients experience little discomfort and can return to normal daily activities relatively quickly, though individual responses vary and clinicians may advise on activity modification in the early weeks. There is no surgical wound to heal and no theatre-related rehabilitation programme, though patience is required for the scaffold to integrate and any regenerative process to progress over months.
- No. Suitability depends on individual assessment — the nature and extent of the cartilage lesion, joint alignment, imaging findings, and overall health all influence whether the injection is appropriate. It is generally better suited to focal lesions and early-to-moderate wear rather than advanced or widespread osteoarthritis. A thorough consultation, including imaging review, is essential before any decision is made.
Where to go from here
A few next steps tailored to what you have just read.
Legal & Medical Disclaimer
This article is written by an independent contributor and reflects their own views and experience, not necessarily those of London Cartilage Clinic. It is provided for general information and education only and does not constitute medical advice, diagnosis, or treatment.
Always seek personalised advice from a qualified healthcare professional before making decisions about your health. London Cartilage Clinic accepts no responsibility for errors, omissions, third-party content, or any loss, damage, or injury arising from reliance on this material.
If you believe this article contains inaccurate or infringing content, please contact us at [email protected].
